CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
Brilacidin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04784897
NCT04784897Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Innovation Pharmaceuticals, Inc.·interventional·Posted Mar 5, 2021·Updated Sep 16, 2022

In Brief

A Phase 2 clinical trial evaluating Brilacidin, Placebo, and 1 other intervention for COVID-19. Completed, enrolled 120 participants across 12 sites in 2 countries.

Detailed Summary

The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesRussia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 5, 2021
Enrollment StartFeb 22, 2021
Primary CompletionJul 1, 2021
Study CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.3 years ago

Interventions

Brilacidindrug

Brilacidin IV infusion

Placebodrug

Placebo IV infusion

Standard of Care (SoC)drug

SoC therapies for COVID-19